Vitamin D3 and Vitamin K2 (MK-7): Can You Take Them Together?

Vitamin D3, once activated to calcitriol (1,25-dihydroxyvitamin D), upregulates the expression of calcium transport proteins in the intestinal epithelium — primarily TRPV6 and calbindin-D9k — increasing calcium absorption from food by as much as 400%. This is the primary mechanism behind vitamin D's role in bone health: more calcium enters the bloodstream, making it available for skeletal mineralization. However, calcitriol also increases expression of osteocalcin in osteoblasts and matrix Gla protein (MGP) in vascular smooth muscle cells. Both of these proteins are synthesized in an inactive, uncarboxylated form. They require vitamin K-dependent gamma-carboxylation to become functional. Without K2, these proteins remain inactive — osteocalcin cannot bind calcium to the bone matrix, and MGP cannot inhibit arterial calcification.

Vitamin K2 as MK-7 (menaquinone-7) is the preferred form for this pairing because of its pharmacokinetic profile. MK-7 has a half-life of approximately 72 hours — far longer than MK-4 (1-2 hours) or vitamin K1 (1-2 hours) — which provides stable, sustained carboxylation activity for both osteocalcin and MGP over the full dosing interval. When D3 raises blood calcium levels but K2 is deficient, calcium accumulates in locations where it causes harm: coronary arteries (atherosclerotic plaque), renal tubules (kidney stones), and joint cartilage. The Rotterdam Heart Study (PMID: 15514282) observed a 57% reduction in coronary heart disease mortality in participants with the highest dietary K2 intake, specifically attributing the benefit to MGP-mediated arterial calcification prevention — the exact protein that D3 upregulates and K2 activates.